Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Oncology|December 31, 2023
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder InjuryKo Nakamura, Takaya Ohno, Teruo Inamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational studyWataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology|May 5, 2019
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in JapanTakuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative StudyTakuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Urologic Oncology|December 28, 2025
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancerTsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, et al.
Stem Cells and Development|July 29, 2016
microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate CancerKiyoshi Takahara, Masaaki Ii, Teruo Inamoto, et al.
Oncotarget|January 5, 2018
The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinomaTakuya Tsujino, Kazumasa Komura, Atsushi Ichihashi, et al.
Journal of Cancer Research and Clinical Oncology|April 9, 2024
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in JapanYosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, et al.
NPJ Precision Oncology|September 17, 2024
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinomaKazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial CarcinomaTeruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
Pageof 9